Related Experiment Video
Updated: Jun 6, 2026

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
Published on: May 9, 2022
The role of obesity as a modifying factor in patients undergoing non-surgical periodontal therapy
Elizangela P Zuza1, Eliane M Barroso, Ana Luiza V Carrareto
1Department of Master of Dental Science Course, School of Dentistry, Educational Foundation of Barretos (UNIFEB), Barretos, Brazil. elizangelazuza@yahoo.com.br
Background:
Earlier studies have shown an association between obesity and periodontitis, which is mediated by cytokine production. The aim of this study is to assess the role of obesity as a modifying factor on periodontal clinical parameters and on circulating proinflammatory cytokine levels in subjects undergoing non-surgical periodontal treatment.
Methods:
Twenty-seven obese subjects and 25 normal-weight subjects were enrolled in this study. Subjects in both groups had generalized chronic periodontitis. The periodontal parameters measured before and 3 months after non-surgical periodontal therapy were: visible plaque index, bleeding gingival index, bleeding on probing, probing depth, and clinical attachment level. In addition, subjects underwent anthropometric measurements and serum analyses of fasting glucose, glycated hemoglobin, interleukin-1β, interleukin-6, tumor necrosis factor-α, and interferon-γ.
Results:
Periodontal therapy significantly decreased visible plaque index, bleeding gingival index, bleeding on probing, probing depth of 4 to 6 mm, probing depth ≥7 mm, clinical attachment level of 4 to 6 mm, and clinical attachment level ≥7 mm in both groups (P ≤0.05). Circulating proinflammatory cytokines significantly decreased in obese and normal-weight subjects after periodontal treatment (P ≤0.05). However, interleukin-6 and tumor necrosis factor-α levels remained higher in obese subjects 3 months after treatment (P ≤0.05).
Conclusion:
Obesity does not seem to play a negative role by interfering in the improvement of the periodontal clinical response or decreasing circulating proinflammatory cytokine levels after periodontal treatment.
Related Concept Videos
Drug Dosing: Obese Patients
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Atherosclerosis III: Management
The Oral Microbiota
Obesity